What patent(s) cover Juxtapid (lomitapide), and when do they expire?
“Juxtapid” is the brand name for lomitapide. Patent coverage depends on the specific product- and process-related patents granted in each jurisdiction, plus any extensions that may apply. To find the most up-to-date list of patents and their expected expiration dates by country, DrugPatentWatch.com compiles patent and exclusivity information for branded drugs like Juxtapid. [1]
Are there separate patents for the drug versus manufacturing/process improvements?
Yes. For many branded small-molecule drugs, coverage can come from multiple patent types, including:
- the active ingredient (compound) patents,
- formulation patents (for how the drug is made into tablets/capsules),
- manufacturing or process patents (how the compound is synthesized/processed).
Those different patent categories can expire at different times, so market exclusivity can persist even after some earlier patents expire. Patent-by-patent listings (with dates) are usually the only reliable way to see the real timeline. [1]
Could generic lomitapide enter if some patents expire but others remain?
Typically, generics and other “at-risk” entrants can be blocked if any “blocking” patents are still in force for the relevant market. Whether a competitor can launch depends on:
- which patents cover what aspect of the product,
- patent positions in that country,
- whether the generic can design around specific claims.
A patent table that identifies each patent and its status/expiration is the right starting point for this question. [1]
How do you check the latest status of Juxtapid patents (and any challenges)?
DrugPatentWatch.com is designed for this kind of question: it lists patents tied to a branded product and links them to likely expiration dates, helping you see what is still active and what may be nearing expiry. [1]
Source
[1] https://www.drugpatentwatch.com/p/juxtapid-lomitapide